{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:45Z","timestamp":1787009445293,"version":"build-2736575974"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NextGeneration EU-MUR PNRR Extended Partnership"},{"name":"Initiative on Emerging Infectious Diseases","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, Klebsiella pneumoniae carbapenemase (KPC)\u2013producing Klebsiella pneumoniae (KPC-Kp) with resistance to ceftazidime\/avibactam (CZA-R) has been described, including KPC variants that restore carbapenem susceptibility. The aim of the study was to analyze the clinical characteristics and outcomes of infections caused by CZA-R KPC-Kp.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2019 to 2021, a retrospective 2-center study including patients with infections due to CZA-R KPC-Kp hospitalized at 2 academic hospitals in Rome was conducted. Demographic and clinical characteristics were collected. Principal outcome was 30-day all-cause mortality. Statistical analyses were performed with Stata-IC17 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 59 patients were included (mean age, 64.4 \u00b1 14.6 years; mean Charlson comorbidity index score, 4.5 \u00b1 2.7). Thirty-four patients (57.6%) had infections caused by CZA-R and meropenem (MEM)\u2013susceptible strains. A previous CZA therapy was observed in 40 patients (67.8%), mostly in patients with MEM-susceptible KPC variant (79.4% vs 52%, P = .026). Primary bacteremia was observed in 28.8%, followed by urinary tract infections and pneumonia. At infection onset, septic shock was present in 15 subjects (25.4%). After adjustment for confounders, only the presence of septic shock was independently associated with mortality (P = .006).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Infections due to CZA-R KPC-Kp often occur in patients who had previously received CZA, especially in the presence of strains susceptible to MEM. Nevertheless, one-third of patients had never received CZA before KPC-Kp CZA-R. Since the major driver for mortality was infection severity, understanding the optimal therapy in patients with KPC-Kp CZA-R infections is of crucial importance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofad327","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T02:52:31Z","timestamp":1687834351000},"source":"Crossref","is-referenced-by-count":23,"title":["Clinical Characteristics and Outcome of Ceftazidime\/Avibactam-Resistant\n                    <i>Klebsiella pneumoniae<\/i>\n                    Carbapenemase\u2013Producing\n                    <i>Klebsiella pneumoniae<\/i>\n                    Infections: A Retrospective, Observational, 2-Center Clinical Study"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-7975","authenticated-orcid":false,"given":"Alessandra","family":"Oliva","sequence":"first","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campogiani","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of System Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Savelloni","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Vitale","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lodi","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederica","family":"Sacco","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Imeneo","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Volpicelli","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Polani","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-0811","authenticated-orcid":false,"given":"Giammarco","family":"Raponi","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of System Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Venditti","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"2023071910522519700_ofad327-B1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023071910522519700_ofad327-B2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023071910522519700_ofad327-B3","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B4","volume-title":"Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae\u201412 June 2018","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2018"},{"key":"2023071910522519700_ofad327-B5","doi-asserted-by":"crossref","first-page":"124.e1","DOI":"10.1016\/j.cmi.2019.08.020","article-title":"Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023071910522519700_ofad327-B6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies","volume":"25","author":"Di Bella","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2023071910522519700_ofad327-B7","doi-asserted-by":"crossref","first-page":"dlac121","DOI":"10.1093\/jacamr\/dlac121","article-title":"Effect of ceftazidime\/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study","volume":"4","author":"Oliva","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023071910522519700_ofad327-B8","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023071910522519700_ofad327-B9","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023071910522519700_ofad327-B11","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1080\/22221751.2021.1984182","article-title":"Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae","volume":"10","author":"Guo","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"2023071910522519700_ofad327-B12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12866-021-02293-0","article-title":"Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime\/avibactam resistance in Klebsiella pneumoniae","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Microbiol"},{"key":"2023071910522519700_ofad327-B13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s12223-021-00918-5","article-title":"Ceftazidime-avibactam: are we safe from class A carbapenemase producers\u2019 infections?","volume":"66","author":"Moreira","year":"2021","journal-title":"Folia Microbiol (Praha)"},{"key":"2023071910522519700_ofad327-B14","doi-asserted-by":"crossref","first-page":"ofx101","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2023071910522519700_ofad327-B15","doi-asserted-by":"crossref","first-page":"e0057421","DOI":"10.1128\/AAC.00574-21","article-title":"Evolutionary trajectories toward ceftazidime-avibactam resistance in Klebsiella pneumoniae clinical isolates","volume":"65","author":"Carattoli","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B16","doi-asserted-by":"crossref","first-page":"e0089021","DOI":"10.1128\/AAC.00890-21","article-title":"KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae","volume":"65","author":"Findlay","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B17","doi-asserted-by":"crossref","first-page":"e02534","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum \u03b2-lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2020.05.001","article-title":"Resistance to novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: the \u201cprice of progress.\u201d","volume":"34","author":"Papp-Wallace","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2023071910522519700_ofad327-B19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jiac.2021.01.014","article-title":"Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: a case series","volume":"27","author":"van Asten","year":"2021","journal-title":"J Infect Chemother"},{"key":"2023071910522519700_ofad327-B20","doi-asserted-by":"crossref","first-page":"1040.e1","DOI":"10.1016\/j.cmi.2021.03.001","article-title":"Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae","volume":"27","author":"Venditti","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023071910522519700_ofad327-B21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jgar.2023.03.012","article-title":"Ceftazidime\/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations","volume":"33","author":"Oliva","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2023071910522519700_ofad327-B22","doi-asserted-by":"crossref","first-page":"e00079","DOI":"10.1128\/AAC.00079-17","article-title":"In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B23","doi-asserted-by":"crossref","first-page":"e01936","DOI":"10.1128\/AAC.01936-19","article-title":"Potency of vaborbactam is less affected than that of avibactam in strains producing KPC-2 mutations that confer resistance to ceftazidime-avibactam","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/1120009X.2021.1909939","article-title":"Looking beyond ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae: in vitro activity of the novel meropenem-vaborbactam in combination with the old fosfomycin","volume":"33","author":"Boattini","year":"2021","journal-title":"J Chemother"},{"key":"2023071910522519700_ofad327-B25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jgar.2019.11.007","article-title":"Use of carbapenems in the combined treatment of emerging ceftazidime\/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature","volume":"22","author":"Cano","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023071910522519700_ofad327-B26","article-title":"Clinical breakpoints\u2014bacteria","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2020"},{"key":"2023071910522519700_ofad327-B27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2023071910522519700_ofad327-B28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023071910522519700_ofad327-B29","article-title":"CDC\/NHSN surveillance definitions for specific types of infections","author":"Centers for Disease Control and Prevention, National Healthcare Safety Network","year":"2023"},{"key":"2023071910522519700_ofad327-B30","article-title":"Pneumonia (ventilator-associated [VAP] and non-ventilator-associated pneumonia [PNEU]) event","author":"Centers for Disease Control and Prevention, National Healthcare Safety Network","year":"2023"},{"key":"2023071910522519700_ofad327-B31","article-title":"Bloodstream infection (BSI) events","author":"Centers for Disease Control and Prevention,. National Healthcare Safety Network","year":"2020"},{"key":"2023071910522519700_ofad327-B32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/infdis\/141.6.781","article-title":"Quantitative culture of intravenous catheters and other intravascular inserts","volume":"141","author":"Cleri","year":"1980","journal-title":"J Infect Dis"},{"key":"2023071910522519700_ofad327-B33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2023071910522519700_ofad327-B34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit Care"},{"key":"2023071910522519700_ofad327-B35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"de Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023071910522519700_ofad327-B36","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein\u2013guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"2023071910522519700_ofad327-B37","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023071910522519700_ofad327-B38","article-title":"Ceftazidime-avibactam resistance in Klebsiella pneumoniae sequence type 37: a decade of persistence and concealed evolution","volume":"9","author":"Arcari","year":"2023","journal-title":"Microb Genom"},{"key":"2023071910522519700_ofad327-B39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10096-021-04388-y","article-title":"Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report","volume":"41","author":"Arcari","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023071910522519700_ofad327-B40","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3390\/microorganisms9112356","article-title":"Ceftazidime\/avibactam-resistant Klebsiella pneumoniae subsp. pneumoniae isolates in a tertiary Italian hospital: identification of a new mutation of the carbapenemase type 3 (KPC-3) gene conferring ceftazidime\/avibactam resistance","volume":"9","author":"Fontana","year":"2021","journal-title":"Microorganisms"},{"key":"2023071910522519700_ofad327-B41","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/jac\/dkz156","article-title":"KPC-31 expressed in a ceftazidime\/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues","volume":"74","author":"Antonelli","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023071910522519700_ofad327-B42","first-page":"e02097","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B43","doi-asserted-by":"crossref","first-page":"dlac022","DOI":"10.1093\/jacamr\/dlac022","article-title":"Compassionate use of meropenem\/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study","volume":"4","author":"Tumbarello","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023071910522519700_ofad327-B44","doi-asserted-by":"crossref","first-page":"516.e1","DOI":"10.1016\/j.cmi.2019.11.011","article-title":"Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime\/avibactam: epidemiology and genomic characterization","volume":"26","author":"Gaibani","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023071910522519700_ofad327-B45","doi-asserted-by":"crossref","first-page":"1172.e7","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC \u03b2-lactamase mutants and the inoculum effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023071910522519700_ofad327-B46","doi-asserted-by":"crossref","first-page":"537.e1","DOI":"10.1016\/j.cmi.2022.11.011","article-title":"Deciphering variable resistance to novel carbapenem-based \u03b2-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)\u2013producing Klebsiella pneumoniae resistant to ceftazidime\/avibactam","volume":"29","author":"Di Pilato","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023071910522519700_ofad327-B47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cmi.2022.01.025","article-title":"In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and\/or meropenem-vaborbactam","volume":"28","author":"Lombardo","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023071910522519700_ofad327-B48","doi-asserted-by":"crossref","first-page":"e0116021","DOI":"10.1128\/AAC.01160-21","article-title":"KPC-39-mediated resistance to ceftazidime-avibactam in a Klebsiella pneumoniae ST307 clinical isolate","volume":"65","author":"Jousset","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023071910522519700_ofad327-B49","doi-asserted-by":"crossref","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad327\/50743720\/ofad327.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad327\/50910527\/ofad327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad327\/50910527\/ofad327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:16:11Z","timestamp":1689750971000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad327\/7210743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad327","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,6,30]]},"article-number":"ofad327"}}